INFORMAZIONI PERSONALI **LORENZO BERETTA**

Email aziendale lorenzo.beretta@policlinico.mi.it

Sesso Maschio Data di Nascita 30/07/1973 Nazione ITALIA

POSIZIONE RICOPERTA DIRIGENTE MEDICO

ESPERIENZA PROFESSIONALE

Da Aprile 2023 DIRIGENTE MEDICO

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

Incarico come Responsabile SS Malattie Autoimmuni Sistemiche

Attività o Settore SANITA'

Da Settembre 2005 DIRIGENTE MEDICO

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

Specialistica ambulatoriale immunologia clinica

Attività o Settore SANITA'

ISTRUZIONE E FORMAZIONE

Da Novembre 1998 a Novembre 2002 Specialista in Immunologia Clinica

Università degli Studi di Milano

Dal 1992 a Ottobre 1998 Laurea in Medicina e Chirurgia

Università degli Studi di Milano

COMPETENZE PERSONALI

Lingua madre: Italiano

Altre lingue

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	C1	C1	C1	C1	C1

Livelli: A 1/2 Livello Base - B 1/2 Livello Intermedio - C 1/2 Livello Avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Competenze comunicative Esperienza completa riguardo alla cura del paziente e ottime capacità di comunicazione con i pazienti

Competenze organizzative e gestionali Ottima capacità organizzative, di coordinamento e gestione delle risorse umane.

Leadership e coordinamento di gruppi di ricerca e clinici interdisciplinari.

Responsabile di gruppi di ricerca o clinici a livello internazionale.

Competenze professionali Diagnosi e terapia delle malattie autoimmuni sistemiche/immuno-reumatologiche.

Competenze informatiche Ottima conoscenza e gestione dei comuni software (videoscrittura, fogli elettronici)

Capacità di programmazione in python e R sviluppo di software per analisi di dati

Patente di guida B

ULTERIORI INFORMAZIONI

Letture presso università o enti stranieri

Invited lecturer at the Utrecht Medical Center (UMC), 21st February 2012. The evolution of Raynaud's Phenomenon: from Early to definite Systemic Sclerosis.
Invited lecturer at the Marqués de Valdecilla University Hospital, Santander 09th September 2014. Title: "A travel into Early Systemic Sclerosis and into the path to definite scleroderma
Invited lecturer at the Utrecht Medical Center (UMC), 30th January 2015. Title: "Raynaud 1862, Systemic Sclerosis 2013 and Beyond.
Invited lecturer at the Leeds University, St. Jame's College, 1st October 2015. Title: "Systemic sclerosis, an evolutive disease. What genetics and immunology have taught us so far?
Invited lecturer at the Utrecht Medical Center (UMC), 7th September 2017. Title: "Microbic and Metabolic multi-omic correlations in systemic sclerosis patients
Invited lecturer at the University of Texas Health (UTH) Center at Houston, 10th November 2017; UTHSC Scleroderma Lecture Series.

Partecipazione a clinical trials

-Prot. A1481166 002/03: A randomised double-blind controlled study to evacuate the potential of Sindenafil for the treatment of Raynuad's phenomenon secondary to Systemic Sclerosis with limited cutaneous involvement. Role: Co-Investigator.
-Prot. n. AC-052-330 002/03 (BUILD2): A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, tolerability and safety of bosentan in patients with interstitial lung disease associated with systemic sclerosis. Role: Co-Investigator.
-Prot. n. AC-052-331 (RAPIDS2): A randomized,double-blind, placebo controlled, multi-center study to assess the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with Systemic Sclerosis. Role: Co-Investigator.
-Studio osservazionale "registro DUO-Registro di pazienti affetti da ulcere digitali associate a sclerodermia. Role: Principal Investigator.
-Prot n. ACT 12339 EUDRACT 2012-001369-34: Double-blind, randomized, placebo-controlled, 8-week study investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients with Diffuse Cutaneous Systemic Sclerosis. Role: Principal Investigator.
-Prot n. CC-4047-SSc-001: A phase 2, proof-of-concept, multicenter, randomized, double blind, placebo-controlled study to evaluate the safety, tolerability, pharmacoknetics, pharmacodynamics and efficacy of pomalidomide (CC-4047) in subjects systemic sclerosis with interstitial lung disease. Role: Prinicipal Investigator.
-Prot ML28699 (EUDRACT 2013-001569-17). Studio nazionale in aperto, a singolo braccio, di fase IIIb per valutare l'efficacia di tocilizumab sottocute, somministrato una volta alla settimana in monoterapia o in combinazione con methotrexato e/o con altri DMARDs in pazienti con Artrite Reumatoide (AR). Role: Principal Investigator.
-Prot EUDRACT 2012-005348-92, PROGASS. Studio per valutare l'effetto della Prucalopride sul transito gastroenterico in pazienti affetti da sclerosi sistemica. Role: Principal Investigator.
-Prot IM101348ST. Esperienza a lungo termine con abatacept sottocute nella pratica clinica: studio ASCORE. Role: Principal Investigator.
-Prot EMR700461-023 (EUDRACT 2013-002773-21). A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE). Role: Prinicipal Investigator. National Coordinator.
-Prot WA29767, FocuSSced. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel'Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis. Principal Investigator.
-Prot ACT14606. Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized double-blind, placebo-controlled. 24-week, proof of concept study.
-Prot EMR200017-014, STRATUS. A Phase II, randomized, double-blind, Placebo-controlled, parallel'group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-interstitial lung diseases (SSc-ILD). Principal investigator
-Prot Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS): Prospective observational cohort of patients with moderate-to-severe SLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes and comorbidities, healthcare resource utilization, and the impact of SLE on quality of life by type I interferon gene expression. Principal investigator.
-Prot 14V-MC-JAIA: A Randomized, Double-Blind, Placebo-Controlled, Parallel'Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus. Principal investigator.
-Protocol ID-064A202: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel'group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE). Principal investigator.
-Protocol AC-077A301: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel'group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose com bination therapy. Principal investigator, national coordinator.
-Prot 14V-MC-JAIM: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE). Principal investigator.
-Prot SL0043: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO). Principal investigator.

-Prot SL0046: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus. Principal investigator.
-Prot MITSUBISHI MT-7117-G02: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis. Principal investigator.
-Prot SL0044: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel'Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus. Principal investigator.
-Prot D3460C00002: A Multicenter, Randomized, Parallel'group, Double-blind,Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis DAISY. Principal Investigator
-Protocol HZNP-DAZ-301: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity. Principal Investigator
-Protocol HZNP-DAZ-303: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-Severe Symptom State. Principal Investigator

Pubblicazioni

Autore di circa 200 articoli su riviste internazionali indicizzate con impact factor.
H index 47

https://www.scopus.com/authid/detail.uri?authorId=7005190165

Riconoscimenti come vinictore di bandi pubblici so

-Progetto CARIPLO 2004, FULL TITLE: Ruolo dei polimorfi genetici nell'espressività clinica e nell'evoluzione della sclerosi sistemica. Role: Co-Investigator.
-IMI Grant 2014-2019, nr115565, ACRONYM: PRECISESADS, FULL TITLE: Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases. Role: Work-package leader.
- GILS (Gruppo Italiano per la Lotta alla Sclerodernia) grant 2014-2016. FULL TITLE: Genetic and Microcirculatory Factors Associated with Systemic Sclerosis Evolution: from Early to Definite scleroderma. Role: Research lead.
-Progetto a Concorso 2014-2016 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano. FULL TITLE: Studio per determinare il ruolo della NETosi nell'autoimmunità in corso di sclerosi sistemica. Role: Research lead.
- GILS (Gruppo Italiano per la Lotta alla Sclerodernia) grant 2015-2016. FULL TITLE: An "omic Approach to Assess the Nutritional Consequences of Systemic-Sclerosis Related Intestinal Involvement. Role: Research lead.
- CREARE 2017 research awards. FULL TITLE: RNAseq profiling of rheumatoid arthritis patients to predict response to tofacitinib (SERRATO). Involvement. Role: Research lead.
-IMI2 Grant 2019-2026, n 831434 , ACRONYM: 3TR, FULL TITLE: TAXONOMY, TREATMENT, TARGETS AND REMISSION. IDENTIFICATION OF THE MOLECULAR MECHANISMS OF NON-RESPONSE TO TREATMENTS, RELAPSES AND REMISSION IN AUTOIMMUNE, INFLAMMATORY, AND ALLERGIC CONDITIONS. Role: Work-package leader.

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n, 196 'Codice in materia di protezione dei dati personali'.